Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02986178 · ClinicalTrials.gov registry record · Phase 2
Lerapolturev in Recurrent Malignant Glioma
A Phase 2 study, sponsored by Istari Oncology.
- Completed
- Registry status
- Phase 2
- Development phase
- 121
- Enrollment target
NCT02986178 is a Phase 2 study that has completed, run by Istari Oncology. The registered enrollment target is 121 participants.
The verdict
NCT02986178, a Phase 2 study, has completed, sponsored by Istari Oncology.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 121 participants
- Enrollment target
Study Summary
This is a phase 2 study of lerapolturev, an oncolytic polio/rhinovirus recombinant, in adult patients with recurrent World Health Organization (WHO) grade IV malignant glioma.
Interventions
- DRUG Lomustine
- BIOLOGICAL lerapolturev
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 121 participants |
| Start Date | 2017-06-01 |
| Est. Completion | 2023-02-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02986178
The ClinicalTrials.gov registry entry for NCT02986178 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 121 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Istari Oncology, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Lomustine is the first listed.
NCT02986178 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02986178 about?
NCT02986178 is a clinical study titled "Lerapolturev in Recurrent Malignant Glioma". This is a phase 2 study of lerapolturev, an oncolytic polio/rhinovirus recombinant, in adult patients with recurrent World Health Organization (WHO) grade IV malignant glioma.
What is the current status of trial NCT02986178?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 121 participants. The study started on 2017-06-01. Estimated completion is 2023-02-03.
What interventions are being tested in trial NCT02986178?
The interventions under investigation include: Lomustine (DRUG), lerapolturev (BIOLOGICAL).
Who is sponsoring clinical trial NCT02986178?
This trial is sponsored by Istari Oncology, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.